Vedolizumab-a new agent for treating IBD

The European Commission (EC) has approved the drug vedolizumab (Entyvio, Takeda Pharmaceuticals) for people with moderate to severe Crohn's disease or Ulcerative colitis who are steroid resistant or dependent, or fail to respond or loose response to immunosupressants such as the anti-TNF agents Humira or Infliximab.
The efficacy of vedolizumab was demonstrated in 2 randomized, double-blind, placebo-controlled trials published in August 2013 in the New England Journal of Medicine.
Vedolizumab is a humanized IgG1 monoclonal antibody that binds exclusively to the α4β7 integrin, a key mediator of gastrointestinal inflammation. This integrin helps immune cells move around the body and specifically to the gut though the blood vessels

Viewpoint: Vedolizumab seems an exciting new drug to be used in people with Crohn’s Disease & Ulcerative Colitis. Previously, the antibody treatments have focused on having an effect of neutralising tumour necrosis factor. This drug has an effect on a completely new arm of the immune system that interferes with the way immune cells find their way around the body, arriving at sites of inflammation. Longer term follow-up will be needed to determine the durability of effect and safety. CMH

Designed by Neovirtua